Foff Erin Pennock 4

What Happened

• Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics (MPLT), was granted two awards on February 5, 2026: 13,360 restricted stock units (RSUs) and 54,240 derivative securities (stock-option style award). Both grants show a $0.00 per-share acquisition price (awards, not open-market purchases or sales).

Key Details

• Transaction date: 2026-02-05; Form 4 filed: 2026-02-09 (filed within the required reporting window).
• RSUs: 13,360 shares awarded at $0.00. Footnote: 1/4 of these RSUs vest on Jan 1, 2027, then 1/16th vest on each subsequent Apr 1, Jul 1, Oct 1 and Jan 1 thereafter (vests with continued service). Each RSU converts to one share of common stock upon vesting.
• Derivative award: 54,240 derivative securities shown as acquired at $0.00. Footnote: 1/4 of the total shares underlying the option vest on Feb 5, 2027, then 1/48th vest each month thereafter (subject to continued service). These are grants of rights to acquire shares subject to vesting.
• Shares owned after the transaction are not specified in the Form 4.
• These are compensation awards (code A), not purchases or sales — not an immediate market buy/sell signal.

Context

• RSUs convert into actual shares only as they vest; they are typically compensation, not a directional insider trade. The derivative awards represent the right to acquire common stock over time per the stated vesting schedule. No exercise price or cash proceeds are reported in this filing.